

Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa

NCT06492850

| | |
|------------|-----------------------|
| Status | RECRUITING |
| Phase | Phase 1, Phase 2 |
| Sponsor | Frontera Therapeutics |
| Enrollment | 32 participants |

Key Eligibility Criteria

Inclusion (3)

- Subjects that are willing and able to follow study procedures including scheduled visits, treatment plan, and laboratory tests, and sign a written informed consent form;
- Age: Phase I dose escalation stage, 18-45 years old male (including boundary value) at the time of signing the ICF; Phase II dose extension stage, males 8-45 years old (including boundary values) at the time of signing the ICF;
- Clinically diagnosed XLRP, the main symptoms include but are not limited to night blindness, visual field loss, vision loss, etc.;

Exclusion (1)

- Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.

Locations (1 total)

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China